Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks bounce back after recent sell-off

Tue, 28th May 2013 11:20

UK markets were registering impressive gains on Tuesday morning with hopes of continued monetary easing in the Eurozone lifting sentiment as stocks bounced back following last week's sharp sell-off.After reaching a 13-year high on Wednesday, the FTSE 100 dropped sharply in the latter part of last week - losing nearly 3.0% in just two days - on fears of a scaling back of stimulus measures from the US Federal Reserve as well as some gloomy economic data from China.However with UK and US markets closed for national holidays on Monday, traders were looking to play catch up after missing out on the previous day's rally. Helping the bullish mood today were comments from European Central Bank (ECB) board member Peter Praet who said that the bank could still cut interest rates if needed to support the economy. In recent interviews, Praet said that "even after cutting the cost of money to a record low of 0.50%, the ECB signalled that the possibility of further easing was not exhausted".Market Analyst Craig Erlam from Alpari said: "Investor sentiment is on the rise in Europe this morning, with stock indices following in the footsteps of their Asian counterparts over night, which recovered early losses to end the session higher." Tuesday's session was the first positive day on Tokyo's Nikkei index since it dropped by 7.3% on Thursday."Now that the dust is beginning to settle, we could be seeing traders take advantage of the dip in the market to buy on the cheap. Given that the Bank of Japan's massive bond buying programme is only just getting under way, I think this will be the case," Erlam said.The economic data calendar was on the light side on Tuesday morning in Europe, though eyes will be fixed on consumer confidence and home-price figures in the States due out this afternoon.FTSE 100: TUI Travel, pharmas and banks provide a liftTour operator TUI Travel was among the best performers this morning, rising in sympathy with French peer Club Mediterranee after its shareholders Fosun International and Axa Private Equity joined forces to make a €540m bid for the firm.Drugs giant AstraZeneca higher after saying that it will continue to "vigorously" defend the intellectual property rights protecting its asthma medicine Pulmicort Respules. The company is appealing against a US court ruling that the patent protecting Pulmicort from rival drugs in the US is invalid. Sector peers Shire and GlaxoSmithKline were also in demand early on, with the latter being boosted by an upgrade by Deutsche Bank to 'buy'.Financial stocks were also performing well as markets on the whole rebounded from last week's sell-off. HSBC, Barclays and Standard Chartered were in positive territory, joined by part-nationalised lenders RBS and Lloyds which were both shrugging off downgrades by Citigroup today.Wood Group was also higher on news that its PSN business will continue to provide duty holder and asset management services to the Hummingbird Spirit floating storage offloading production vessel, under a new contract extension worth $87m from Teekay. Positive comments from Bank of America Merrill Lynch were helping share prices of a number of retailers this morning after the broker raised its target prices for Sainsbury, Marks & Spencer and Tesco.FTSE 250: Victrex jumps after first-half reportPolymer manufacturer Victrex was a high riser on the second-tier index after increasing its interim dividend by 15% despite a slight fall in profits. The company however still managed to beat profit before tax forecasts by 2.0% in the first half.Soft drinks maker AG Barr was also up as it managed to increase revenues by 2.4% in the first quarter in spite of the dismal weather.Mining firm Kazakhmys was heading the other way after announcing that it has sold its long-held German copper products unit MKM for €42m. "MKM is an excellent business, but did not fit with our geographic and strategic focus as a natural resources company in Central Asia," the company said.FTSE 100 - RisersPetrofac Ltd. (PFC) 1,391.00p +3.81%Barclays (BARC) 328.95p +3.77%TUI Travel (TT.) 371.50p +3.63%CRH (CRH) 1,438.00p +3.45%Weir Group (WEIR) 2,373.00p +3.40%Melrose Industries (MRO) 263.70p +3.33%GKN (GKN) 305.90p +3.21%International Consolidated Airlines Group SA (CDI) (IAG) 281.60p +3.15%Babcock International Group (BAB) 1,202.00p +3.09%AstraZeneca (AZN) 3,534.00p +3.09%FTSE 100 - FallersEurasian Natural Resources Corp. (ENRC) 249.00p -2.28%Randgold Resources Ltd. (RRS) 4,921.00p -1.34%Severn Trent (SVT) 2,049.00p -1.06%Anglo American (AAL) 1,549.00p -0.48%United Utilities Group (UU.) 784.00p -0.38%Carnival (CCL) 2,229.00p -0.36%Glencore Xstrata (GLEN) 331.75p -0.03%Rio Tinto (RIO) 2,866.50p -0.02%FTSE 250 - RisersNew World Resources A Shares (NWR) 115.20p +8.88%Victrex (VCT) 1,720.00p +5.65%Pace (PIC) 260.00p +4.00%Ferrexpo (FXPO) 177.20p +3.99%Telecity Group (TCY) 979.50p +3.93%Laird (LRD) 212.10p +3.87%Inchcape (INCH) 569.50p +3.73%Ashtead Group (AHT) 655.00p +3.39%Spirax-Sarco Engineering (SPX) 2,881.00p +3.37%Homeserve (HSV) 263.60p +3.37%FTSE 250 - FallersHochschild Mining (HOC) 241.30p -2.43%Kazakhmys (KAZ) 318.40p -2.36%AZ Electronic Materials SA (DI) (AZEM) 316.30p -2.23%Kenmare Resources (KMR) 31.00p -2.08%Dunelm Group (DNLM) 854.00p -1.84%EnQuest (ENQ) 131.50p -1.28%Telecom Plus (TEP) 1,271.00p -1.24%Salamander Energy (SMDR) 164.80p -1.20%HICL Infrastructure Company Ltd (HICL) 128.60p -1.08%Carpetright (CPR) 635.00p -1.01%
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.